Power Law company profile

Ra Pharmaceuticals

Biotech & Life Sciences · Cambridge, United States · Founded 2008 · IPO 2016 Unicorn

← All companies

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation

$2.30B

Market cap · 2026

Investors

8 investors on Ra Pharmaceuticals's cap table

Sourced from Dealroom's funding history. Tap any card for that investor's profile.

Series B+ 8 investors entered at this stage

RA Capital Management

Novartis Venture Fund

Morgenthaler Ventures

Patent intelligence

$30M patent portfolio · 18 active families

Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with topic prominence vs same-sector peers.

Estimated portfolio value

$30M

1.3% of market cap · 9.1× smaller than top peer argenx ($275M)

18 active patent families

Where Ra Pharmaceuticals innovates Molecular biologyComplement activityBiochemistryCell biologyPharmacology

Tech-focus vs peers

Where Ra Pharmaceuticals concentrates inside the peer cluster

Axes are the most-shared Patsnap topics across Ra Pharmaceuticals and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).

Compare against

Top-topic prominence (rank inverted, 0–100)

Source: Dealroom Patent Intelligence · Patsnap top-10 topics per company

This is teaser data. The full per-sub-category breakdown, individual patent records, and quality-score history are on the Dealroom platform — request a demo to access.

See Ra Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Open in Dealroom Book a demo